Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CHRS Stock Forecast 2026-2027
$1.39
Current Price
$222.12M
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CHRS Price Targets
+763.3%
To High Target of $12.00
+403.6%
To Median Target of $7.00
+187.8%
To Low Target of $4.00
CHRS Price Momentum
-9.7%
1 Week Change
0.0%
1 Month Change
+54.4%
1 Year Change
-2.1%
Year-to-Date Change
-46.9%
From 52W High of $2.62
+71.6%
From 52W Low of $0.81
📊 TOP ANALYST CALLS
Did CHRS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Coherus is one of their latest high-conviction picks.
Latest CHRS Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, CHRS has a bullish consensus with a median price target of $7.00 (ranging from $4.00 to $12.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $1.39, the median forecast implies a 403.6% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CHRS Analyst Ratings
6
Buy
1
Hold
0
Sell
CHRS Price Target Range
Low
$4.00
Average
$7.00
High
$12.00
Current: $1.39
Latest CHRS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CHRS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 11, 2026 | Guggenheim | Buy | Initiates | $12.00 | |
| Jan 22, 2026 | Oppenheimer | Outperform | Initiates | $N/A | |
| Sep 4, 2025 | Maxim Group | Buy | Upgrade | $N/A | |
| Apr 29, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 24, 2025 | UBS | Neutral | Maintains | $N/A | |
| Mar 11, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 23, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 5, 2024 | Baird | Outperform | Maintains | $N/A | |
| Dec 4, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 8, 2024 | Baird | Outperform | Maintains | $N/A | |
| Nov 7, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 16, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 16, 2024 | UBS | Neutral | Downgrade | $N/A | |
| Aug 5, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 1, 2024 | Baird | Outperform | Maintains | $N/A | |
| May 24, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 13, 2024 | Truist Securities | Buy | Maintains | $N/A | |
| May 10, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 20, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A |
Coherus Biosciences Inc. (CHRS) Competitors
The following stocks are similar to Coherus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Coherus Biosciences Inc. (CHRS) Financial Data
Coherus Biosciences Inc. has a market capitalization of $222.12M with a P/E ratio of 3.1x. The company generates $46.88M in trailing twelve-month revenue with a 397.3% profit margin.
Revenue growth is +62.0% quarter-over-quarter, while maintaining an operating margin of -293.7% and return on equity of +275.4%.
Valuation Metrics
Market Cap
$222.12M
Enterprise Value
$114.07M
P/E Ratio
3.1x
PEG Ratio
-0.1x
Price/Sales
4.8x
Growth & Margins
Revenue Growth (YoY)
+62.0%
Gross Margin
+69.0%
Operating Margin
-293.7%
Net Margin
+397.3%
EPS Growth
+62.0%
Financial Health
Cash/Price Ratio
+77.9%
Current Ratio
1.6x
Debt/Equity
69.2x
ROE
+275.4%
ROA
-32.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Coherus Biosciences Inc. (CHRS) Business Model
About Coherus Biosciences Inc.
What They Do
Develops oncology therapeutics and biosimilars.
Business Model
The company operates as a commercial-stage biopharmaceutical firm, generating revenue primarily through the sale of its FDA-approved oncology therapeutics, including LOQTORZI and UDENYCA. It also focuses on developing innovative treatments and leveraging partnerships to enhance its product offerings and advance its pipeline of clinical candidates.
Additional Information
Founded in 2010 and headquartered in Redwood City, California, Coherus Biosciences emphasizes proprietary combinations in immuno-oncology and has a diversified portfolio that includes treatments for various cancers. Its ongoing research includes mid-stage clinical candidates targeting solid tumors, reflecting a commitment to addressing significant unmet medical needs in oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
145
CEO
Mr. Dennis M. Lanfear
Country
United States
IPO Year
2014
Website
www.coherus.comCoherus Biosciences Inc. (CHRS) Latest News & Analysis
Latest News
Quick Summary
The first patient has been dosed in a Phase 1 study for ZM008, an anti-LLT1 monoclonal antibody, combined with LOQTORZI, a next-generation PD-1 inhibitor.
Why It Matters
The Phase 1 study's initiation for ZM008 and LOQTORZI could signify potential breakthroughs in cancer treatment, influencing market sentiment and stock performance for the involved biotech companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Coherus Oncology Q1 Earnings Call Highlights
2 months ago
Quick Summary
Coherus Oncology (NASDAQ: CHRS) anticipates revenue growth from its drug LOQTORZI for nasopharyngeal cancer through 2026 and plans multiple clinical data releases in its oncology pipeline this year.
Why It Matters
Coherus Oncology's projected revenue growth for LOQTORZI and upcoming clinical data readouts could signal increased market confidence and potential stock price appreciation.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
Coherus Oncology, Inc. (CHRS) held its Q1 2026 earnings call, discussing financial performance and strategic developments. Further details on earnings and outlook were provided.
Why It Matters
Coherus Oncology's Q1 2026 earnings reveal financial performance and strategic direction, influencing stock valuation and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
2 months ago
Quick Summary
LOQTORZI® generated $11.8 million in Q1 2026. Patient accrual for a Phase 2 trial of anti-IL27 is complete. The company has $167 million in cash and securities. Conference call scheduled for 5 PM EDT.
Why It Matters
LOQTORZI® revenue indicates market traction; successful trial completion and drug development enhancements signal potential growth. Strong cash position supports ongoing projects and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Coherus Oncology (CHRS) reported a quarterly loss of $0.25 per share, worse than the expected loss of $0.18, but an improvement from a loss of $0.35 per share a year prior.
Why It Matters
Coherus Oncology's larger-than-expected loss may raise concerns about its financial health, while a reduced loss year-over-year could indicate improving performance, impacting investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Coherus Oncology (CHRS) is rated a Buy, with key data readouts for casdozokitug in mid-2026 and ongoing trials for toripalimab. Current liquidity covers 2-3 quarters; further financing may be required.
Why It Matters
Coherus Oncology's advancing immunotherapy pipeline and upcoming data readouts present potential growth opportunities, but liquidity concerns could impact short-term financial stability.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About CHRS Stock
What is Coherus Biosciences Inc.'s (CHRS) stock forecast for 2027?
Based on our analysis of 1 Wall Street analysts, Coherus Biosciences Inc. (CHRS) has a median price target of $7.00. The highest price target is $12.00 and the lowest is $4.00.
Is CHRS stock a good investment in 2027?
According to current analyst ratings, CHRS has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CHRS stock?
Wall Street analysts predict CHRS stock could reach $7.00 in the next 12 months. This represents a 403.6% increase from the current price of $1.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Coherus Biosciences Inc.'s business model?
The company operates as a commercial-stage biopharmaceutical firm, generating revenue primarily through the sale of its FDA-approved oncology therapeutics, including LOQTORZI and UDENYCA. It also focuses on developing innovative treatments and leveraging partnerships to enhance its product offerings and advance its pipeline of clinical candidates.
What is the highest forecasted price for CHRS Coherus Biosciences Inc.?
Price targets from Wall Street analysts for CHRS are not currently available. The stock is trading at $1.39.
What is the lowest forecasted price for CHRS Coherus Biosciences Inc.?
The lowest price target for CHRS is $4.00 from at , which represents a 187.8% increase from the current price of $1.39.
What is the overall CHRS consensus from analysts for Coherus Biosciences Inc.?
The overall analyst consensus for CHRS is bullish. Out of 1 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are CHRS stock price projections?
Stock price projections, including those for Coherus Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:19 AM UTC